Neuropace
NPCE
51 hedge funds and large institutions have $109M invested in Neuropace in 2024 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 16 increasing their positions, 14 reducing their positions, and 21 closing their positions.
10,600% more call options, than puts
Call options by funds: $214K | Put options by funds: $2K
14% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 14
3.01% more ownership
Funds ownership: 47.15% → 50.16% (+3%)
6% less funds holding
Funds holding: 54 → 51 (-3)
14% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 21
38% less capital invested
Capital invested by funds: $176M → $109M (-$67.3M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$6.6M |
| 2 |
BlackRock
New York
|
+$6.02M |
| 3 |
KLC
Kent Lake Capital
Reno,
Nevada
|
+$5.05M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.83M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.76M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$6.03M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$2.06M |
| 3 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$1.63M |
| 4 |
Goldman Sachs
New York
|
-$1.17M |
| 5 |
EI
EAM Investors
Solana Beach,
California
|
-$998K |
NPCE Hedge Fund Activity: Q2 2024 in Review
51 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Neuropace (NPCE) for Q2 2024, worth a combined $109M — down 38% from $176M a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of NPCE and 18 opened new positions — a net loss of 3 holders — while 14 trimmed existing stakes and 16 added.
The largest buyer was Deutsche Bank, opening a new position worth an estimated $6.6M. The largest seller was OrbiMed, cutting an estimated $6.03M.
- 51 institutional investors held Neuropace (NPCE) as of Q2 2024, down from 54 in Q1 2024.
- Funds reported $109M of Neuropace stock for Q2 2024, down 38% quarter-over-quarter.
- 18 funds opened new Neuropace positions in Q2 2024 and 21 closed out, a net change of -3 holders.
- The largest Neuropace buyer in Q2 2024 was Deutsche Bank, an estimated $6.6M added.
- The largest Neuropace seller in Q2 2024 was OrbiMed, an estimated $6.03M sold.
Based on aggregated 13F filings for Q2 2024.